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Abstract
Background: Presumptive treatment for malaria is common in resource-limited settings, yet controversial given the
imprecision of clinical diagnosis. The researchers compared costs of diagnosis and drugs for two strategies: (1)
empirical treatment of malaria via clinical diagnosis; and (2) empirical diagnosis followed by treatment only with
Giemsa smear confirmation.
Methods: Patients with a diagnosis of clinical malaria were recruited from a mission/university teaching hospital in
southwestern Nigeria. The patients underwent free Giemsa thick (diagnosis) and thin (differentiation) smears, but
paid for all anti-malarial drugs. Clinical diagnosis was made on clinicians’ judgments based on symptoms, including
fever, diarrhoea, headache, and body aches. The paediatric regimen was artesunate (6-9 tablets of 3 mg/kg on day
one and 1.5 mg/kg for the next four days) plus amodiaquine (10 mg/kg day 1-2 and 5 mg/kg on day three in
suspension). Adults were given two treatment options: option one (four and one-half 50 mg artesunate tablets on
day one and nine tablets for the next four days, plus three 500 mg sulphadoxine/25 mg pyrimethamine tablets)
and option two (same artesunate regimen plus nine 200 mg tablets of amodiaquine at 10 mg/kg day 1-2 and 5
mg/kg on day three). The researchers calculated the costs of smears/drugs from standard hospital charges.
Results: Doctors diagnosed 304 patients (170 adults ages >16 years and 134 pediatric) with clinical malaria,
prescribing antimalarial drugs to all. Giemsa thick smears were positive in 115/304 (38%). The typical patient cost
for a Giemsa smear was 550 Naira (US$3.74 in 2009). For children, the cost of testing all, but treating only Giemsa
positives was N888 ($6.04)/child; the cost of empiric treatment of all who were clinically diagnosed was lower,
N660 ($4.49)/child. For adults, the cost of testing all, but treating only Giemsa positives was N711 ($4.84)/adult for
treatment option one (artesunate and sulphadoxine/pyrimethamine) and N730 ($4.97)/adult for option two
(artesunate and amodiaquine). This contrasts to lower costs of empiric treatment for both options one (N610 =
$4.14/adult) and two (N680=$4.63/adult).
Conclusions: Empiric treatment of all suspected cases of malaria was cheaper (at the end of the dry to the
beginning of the rainy season) than only treating those who had microscopy-confirmed diagnoses of malaria, even
though the majority of patients suspected to have malaria were negative via microscopy. One can acknowledge
that giving many malaria-uninfected Nigerians anti-malarial drugs is undesirable for both their personal health and
fears of drug resistance with overuse. Therefore, funding of rapid diagnostic tests whose performance exceeds the
Giemsa smear is needed to achieve an ideal of diagnostic confirmation before treatment.
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Empiric treatment for malaria is the norm in many
resource-limited settings, and is usually based upon
non-specific findings such as fever, body aches, diar-
rhoea, and splenomegaly (especially in children). Empiric
treatment remains controversial since many patients
who do not have malaria are treated as such [1,2]. Since
Nigerian health care is largely fee-for-service, the addi-
tive cost of laboratory tests along with the cost of drugs
may be prohibitive for malaria patients. Nigerian
patients typically ask for treatment and forego a blood
test. Malaria is Nigeria’s leading cause of morbidity, and
the direct loss to the economy of malaria infections is
≈132 billion Naira (US$898 billion at 147 Naira per U.S.
dollar) [3,4]. The current Nigerian “gold standard” is the
Giemsa thick smear; newer rapid diagnostic tests
(RDTs) give convenient and quick results, but are
expensive and sometimes less sensitive [5-8].
The researchers determined how many of the empiri-
cally treated malaria cases were positive by Giemsa stain
and microscopy. The researchers then assessed whether
it would be more cost-effective to treat everyone empiri-
cally versus testing everyone with suspected malaria and
treating those who are positive on Giemsa smear.
Methods
All patients who were clinically diagnosed with malaria
and treated at Baptist Medical Centre (also known as
the Bowen University Teaching Hospital) in Ogbomoso,
Nigeria (northern Oyo state) were enrolled in this study
from May 23 to July 13, 2009. This corresponds to the
tail end of dry season and the beginning of the rainy
season. The researchers’ patients presented at three of
four primary care sites in the hospital: the adult outpati-
ent clinic, the paediatric outpatient clinic, and the emer-
gency room. The study did not enroll in the obstetrics/
gynaecology clinic.
The researchers provided free malaria testing using
Giemsa stains to all patients (adult and paediatric), com-
paring results with empirical diagnoses based on a doctor’s
history and physical examination (nurses and clinical offi-
cers did not make final diagnoses). Clinicians suspected
malaria when patients had a constellation of fever, body-
and headaches, splenomegaly (children), and/or diarrhoea.
No training for malaria diagnosis was given.
A certified haematologist who had received recent
WHO malaria diagnosis training reviewed the smears.
Due to lax pharmaceutical law enforcement, many drugs
(or counterfeits) can be obtained over-the-counter. The
researchers recorded whether or not patients took any
prior medical treatment for malaria in order to judge the
possibility of false negative results. The cost for each
smear was based upon charges to patients at the hospital,
and the supplies for these smears are listed (Table 1).
Patients had to pay for their own medicines, as would
normally be the case. The paediatric regimen was arte-
sunate (6-9 tablets of 3 mg/kg on day one and 1.5 mg/
kg for the next four days) plus amodiaquine (10 mg/kg
on days one to two and 5 mg/kg on day three in sus-
pension). Adults were given two treatment options:
option one (four and one-half 50 mg artesunate tablets
on day one and nine additional artesunate tablets over
the next four days, plus three 500 mg sulphadoxine/25
mg pyrimethamine tablets) and option two (four and
one-half 50 mg artesunate tablets on day one and nine
additional artesunate tablets for the next four days plus
nine 200 mg tablets of amodiaquine at a dose of 10 mg/
kg on day one to two and 5 mg/kg on day three). As
with diagnostics, the researchers calculated the costs of
drugs from these standard medical center charges. Chi
square tests were used for testing statistical significance.
Results and Discussion
Clinicians diagnosed 304 patients (170 adults and 134
children under 16) with presumptive malaria; all were
treated. Of the 304 tests, 115 were Giemsa thick smear
positive (38%) and 189 (62%) were negative (none with
missing data Table 2). Of the 304 patients, 99 (33%) had
taken anti-malarials after the onset of symptoms, but
prior to presentation in the clinic.
Of the 170 adults, 47 (28%) presented having taken
some type of anti-malarial drug. Among persons who
had taken anti-malarials prior to clinical presentation,
26% (12/47) were Giemsa smear positive, compared to
27% (33/123) of those who had not taken anti-malarials
(p = 0.9, Table 3). Of the 134 children, 52 (39%) were
reported to have taken anti-malarial drugs prior to pre-
sentation, while 82 (61%) had not. Among the children
who consumed anti-malarials prior to presentation, 38%
(20/52) were Giemsa smear positive, compared to 61%
(50/82) of children who had not taken anti-malarials (p
= 0.01, Table 4).
The patient cost of one Giemsa smear was 550 Naira
(US$3.74 in 2009). The cost of testing all and treating
only Giemsa positive children was N888 (US$6.04)/pae-
diatric patient; empiric treatment of clinically diagnosed
children was N660 (US$4.49)/paediatric patient. The
cost of testing all and treating only Giemsa positive
adults was N711 (US$4.84)/adult for treatment option
one and N730 (US$4.97)/adult for option two. The
respective costs for empiric treatment of all adult
patients for treatment option one was N610 (US$4.14)/
adult and N680 (US$4.63)/adult for option two.
Giemsa thin smears were done on all patients, demon-
strating that each positive Giemsa thick smear was a
result of Plasmodium falciparum. By varying the theore-
tical costs of diagnostic tests, the researchers found that
for the treatment costs to start to favour a Giemsa
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would have to drop from N550 (US$3.74) to N448 (US
$3.05) and N500 (US$3.40) for adults using treatment
options one and two, respectively. For children, the
Giemsa charge would have to drop further to N318 (US
$2.16). The study did not consider false negative Giemsa
smears for very low parasitaemia levels in the model.
The researchers found that empirical treatment of
those clinically diagnosed with malaria was more cost
effective than testing everyone with Giemsa and then
treating only those who were smear-positive. Due to
limited resources in most malarious countries and the
patient costs and logistical obstacles of the diagnostic
testing, it is easy to understand that presumptive therapy
remains the backbone of most malaria control efforts in
Africa. Saving money is not the only consideration;
more extensive antimalarial use may stimulate inap-
propriate use and drug resistance. Hence, the availability
of inexpensive rapid drug tests to achieve high sensitiv-
ity and high specificity in diagnosis would be optimal if
the diagnostic costs were roughly offset by the savings
in unnecessary therapy. If hospital charges dropped by
18.4% for treatment option one and 9.1% for treatment
option two, then treating only Giemsa positive adults
would be cost-effective. For children, Giemsa smear
charges would have to drop by 42.1% for children to
favour the laboratory-based diagnostic strategy with cur-
rent drug costs. The fact that this Nigerian mission hos-
pital had more doctors than non-physician practitioners
making malaria diagnoses is unlikely to affect the gener-
alizability of these findings; costs used were those of the
hospital, including provider salaries. If lower paid practi-
tioners are doing the syndromic diagnosis of malaria
elsewhere, the costs of empiric therapy are likely to be
even more favorable than with laboratory confirmation.
A 2009 study in Nigeria reported the use of presump-
tive treatment to be more cost-effective than micro-
scopy, noting that a “43.1% prevalence level showed an
incremental cost effectiveness ration (ICER) of 221 per
deaths averted between Rapid Diagnostic Tests (RDT)
and presumptive treatment while microscopy is domi-
n a t e da tt h a tl e v e l . ” The study did not examine the use
of RDTs as they are not commonly used (or even avail-
able) in many Nigerian health care practices, and are
more costly than Giemsa in any case. RDT-directed
therapy may be a viable option when prevalence is
lower and RDT costs are subsidized [9-13]. A 2008
study in Ghana found that under ideal field conditions
and with low and moderate malaria prevalence levels,
rapid diagnostic tests (RDTs) would be more cost
Table 1 Materials and costs for laboratory diagnoses by Giemsa staining at the Baptist Medical Centre/Bowen
University, 2009
Cost of Supplies in bulk Cost of materials
for each test
Materials used for a
Giemsa thick smear
Materials used for a
Giemsa thin smear
▪ Methanol: N5,500/2.5L
▪ Slides: N200/50 slides
▪ EDTA tube: N21,000/1500
▪ (Blood lancets) N600/200
▪ Syringes and Needles N1800/100
▪ Giemsa Stain N3500/500 mL
▪ Buffer salts (Disodium hydrogen orthophosphate
and potassium dihydrogen orthophosphate) N3500/kg
▪ Cover Slips: N250/100
▪ Immersion Oil: N2,500/100 mL
▪ EDTA tube N14
▪ Giemsa Stain:
N3.11
▪ Methanol fix N8.8
▪ Slide: N4
▪ Cover slip: N2.5
▪ Syringe: N18
▪ Buffer (Giemsa):
N0.26
▪ Lancet: N3
▪ 4 mL buffer (1 part stain
to 9 parts buffer)
▪ 0.44 mL Giemsa Stain
▪ 4 mL of Buffer to wash
slide
▪ 0.05 mL of oil for
microscope viewing
▪ 1 EDTA Tube
▪ 1 Slide
▪ 1 Cover Slip
▪ 1 syringe and needle
▪ 4 mL buffer (1 part stain
to 9 parts buffer)
▪ 0.44 mL Giemsa Stain
▪ 4 mL of Buffer to wash
slide
▪ 0.05 mL of oil for
microscope viewing
▪ 4 mL Methanol for
fixation
▪ 1 EDTA Tube
▪ 1 Slide
▪ 1 Cover Slip
▪ 1 syringe and needle
Note: N. stands for Naira, the Nigerian currency. EDTA stands for ethylenediaminetetraacetic acid, a blood preservative.
Table 2 Comparison of Adult and Pediatric Patients
Adult (N = 170) Pediatric (N = 134) P-value
Consumed antimalarials prior to visit 28% (47) 39% (52) 0.039
Did not consume prior antimalarials 72% (123) 61% (82)
Female 61% (104) 40% (54) <0.001
Male 39% (66) 60% (80)
Giemsa Stain Blood Smear Negative (-) 74% (125) 48% (64) <0.001
Giemsa Stain Blood Smear Positive (+) 26% (45) 52% (70)
Note: P values using Chi-square test.
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estingly, the authors suggested that under more “real
world” operational conditions, “microscopy becomes
more cost beneficial than rapid diagnostic tests [12].”
A strength of this study was that 100% of the medical
records and needed data were secured for the 304
patients eligible for the study over the defined study
period. This reflects an unusually good record system at
the Baptist Medical Centre. A limitation of this study
was that it was conducted at only one center serving an
urban and peri-urban region of ≈1 million low income
Nigerians, limiting the generalizabilty of the findings.
This study does not include costs of anti-malarial treat-
ments that persons might have taken before coming to
the hospital.
Conclusion
This study found that the least expensive approach to
malaria treatment in Nigeria with direct real-world costs
in 2009 was treatment of those suspected to have
malaria based upon symptoms at the end of the dry to
the beginning of the rainy season. However, most pre-
sumptive malaria treatments are going to Giemsa smear
negative persons. One can acknowledge that giving
many malaria-uninfected Nigerians anti-malarial drugs
is undesirable for both personal health and fears of drug
resistance with overuse. The ideal solution would be a
simple, cheaper, sensitive, and specific malaria test that
offers affordable rapid diagnosis to reduce false positive
treatments without missing the diagnosis of malaria. In
the meantime, it will be necessary for donors to fund
both treatment and RDTs to achieve optimized drug uti-
lization in Africa.
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